Cresco Ltd.
Cresco Ltd. (CEJOF) Financial Performance & Income Statement Overview
Analyze Cresco Ltd. (CEJOF) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Cresco Ltd. (CEJOF) Income Statement & Financial Overview
View the income breakdown for Cresco Ltd. CEJOF across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $15.66B | $14.60B | $14.75B | $13.76B |
| Cost of Revenue | $12.48B | $11.64B | $11.70B | $11.34B |
| Gross Profit | $3.18B | $2.96B | $3.05B | $2.42B |
| Gross Profit Ratio | $0.20 | $0.20 | $0.21 | $0.18 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $1.29B | $1.36B | $1.25B | $1.50B |
| Operating Expenses | $1.35B | $1.42B | $1.31B | $1.55B |
| Total Costs & Expenses | $13.83B | $13.05B | $13.010B | $12.89B |
| Interest Income | $50.47M | $71.15M | $0.00 | $65.73M |
| Interest Expense | $2.58M | $2.74M | $2.87M | $3.05M |
| Depreciation & Amortization | $160.12M | $130.25M | -$38.56M | $160.05M |
| EBITDA | $2.05B | $1.68B | $1.70B | $1.03B |
| EBITDA Ratio | $0.13 | $0.11 | $0.12 | $0.07 |
| Operating Income | $1.83B | $1.55B | $1.74B | $870.02M |
| Operating Income Ratio | $0.12 | $0.11 | $0.12 | $0.06 |
| Other Income/Expenses (Net) | $53.29M | $61.14M | -$41.44M | $186.42M |
| Income Before Tax | $1.88B | $1.61B | $1.70B | $1.06B |
| Income Before Tax Ratio | $0.12 | $0.11 | $0.12 | $0.08 |
| Income Tax Expense | $404.20M | $559.49M | $573.98M | $300.33M |
| Net Income | $1.48B | $1.05B | $1.12B | $756.11M |
| Net Income Ratio | $0.09 | $0.07 | $0.08 | $0.05 |
| EPS | $35.86 | $26.31 | $27.22 | $18.35 |
| Diluted EPS | $35.86 | $25.41 | $26.76 | $18.35 |
| Weighted Avg Shares Outstanding | $41.24M | $41.24M | $41.25M | $41.20M |
| Weighted Avg Shares Outstanding (Diluted) | $41.24M | $41.24M | $41.97M | $41.20M |
The company's financials show resilient growth, with revenue advancing from $13.76B in Q1 2024 to $15.66B in Q4 2024. Gross profit remained healthy with margins at 20% in Q4 2024 compared to 18% in Q1 2024. Operating income hit $1.83B last quarter, sustaining a consistent 12% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $2.05B. Net income rose to $1.48B, while earnings per share reached $35.86. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan